Business
Crescita Therapeutics Announces the Results of its Annual General Meeting of Shareholders
Crescita Therapeutics Announces the Results of its Annual General Meeting of Shareholders ...
About this update from Crescita Therapeutics, Inc.
[{"type":"text","content":"\n\n\n\nCrescita Therapeutics Announces the Results of its Annual General Meeting of Shareholders\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prngen4{\nBORDER-TOP:1pt; BORDER-RIGHT:black 2pt double; VERTICAL-ALIGN: TOP; BORDER-BOTTOM:black 2pt double; TEXT-ALIGN: CENTER; PADDING-LEFT:0.50em; BORDER-LEFT:1pt; PADDING-RIGHT:0.50em\n}\n.prngen5{\nBORDER-TOP:1pt; BORDER-RIGHT:black 2pt double; VERTICAL-ALIGN: TOP; BORDER-BOTTOM:black 2pt double; TEXT-ALIGN: CENTER; PADDING-LEFT:0.50em; BORDER-LEFT:black 2pt double; PADDING-RIGHT:0.50em\n}\n.prngen6{\nBORDER-TOP:1pt; BORDER-RIGHT:black 2pt double; VERTICAL-ALIGN: TOP; BORDER-BOTTOM:black 2pt double; TEXT-ALIGN: CENTER; PADDING-LEFT:0.50em; BORDER-LEFT:1pt; PADDING-RIGHT:1.17em\n}\n.prngen2{\nBORDER-TOP:black 2pt double; BORDER-RIGHT:black 2pt double; VERTICAL-ALIGN: MIDDLE; BORDER-BOTTOM:black 2pt double; TEXT-ALIGN: CENTER; PADDING-LEFT:0.50em; BORDER-LEFT:black 2pt double; PADDING-RIGHT:0.50em\n}\n.prngen3{\nBORDER-TOP:black 2pt double; BORDER-RIGHT:black 2pt double; VERTICAL-ALIGN: TOP; BORDER-BOTTOM:black 2pt double; TEXT-ALIGN: CENTER; PADDING-LEFT:0.50em; BORDER-LEFT:1pt; PADDING-RIGHT:0.50em\n}\n.prntblns{\nBORDER-TOP: 1pt; BORDER-RIGHT: 1pt; BORDER-COLLAPSE: collapse; BORDER-BOTTOM: 1pt; BORDER-LEFT: 1pt\n}\n\n\n\n\n\n\n\nCanada NewsWire\nLAVAL, QC, May 14, 2020\n\n\n\nLAVAL, QC, May 14, 2020 /CNW/ - Crescita Therapeutics Inc. (TSX: CTX) (OTC US: CRRTF) (\"Crescita\" or the \"Company\"), a growth-oriented, innovation-driven Canadian commercial dermatology company with in-house research & development (\"R&D\") and manufacturing capabilities, today announced the voting results from its 2020 Annual General Meeting of Shareholders held at its corporate headquarters in Laval, Québec. \n\n \n \n \n \n \n \n\n \nThe detailed results of the votes received by proxy are as follows:\nElection of Directors\nDirector Nominees\nNUMBER OF SHARES\nPERCENTAGE OF VOTES CAST\nFOR\nWITHHELD\nFOR\nWITHHELD\nDaniel N. Chicoine\n2,821,612\n65,758\n97.7%\n2.3%\nDavid A. Copeland\n2,817,667\n69,703\n97.6%\n2.4%\nAnth...